Regulated Information

Filter

Period

Filter by

recent search

Showing: 105 of 131 Regulated Information

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A.


Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital


Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.


Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PARIS, FRANCE; BOSTON, U.S., 22 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The…


Ipsen publishes its 2023 Universal Registration Document
Ipsen publishes its 2023 Universal Registration Document

Ipsen publishes its 2023 Universal Registration Document


1 2 3 4 5 6 7 27